204 related articles for article (PubMed ID: 30638934)
41. An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer.
Noguchi S; Saito A; Horie M; Mikami Y; Suzuki HI; Morishita Y; Ohshima M; Abiko Y; Mattsson JS; König H; Lohr M; Edlund K; Botling J; Micke P; Nagase T
Clin Cancer Res; 2014 Sep; 20(17):4660-72. PubMed ID: 24951773
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the HOXA11 level in patients with lung squamous cancer and insights into potential molecular pathways via bioinformatics analysis.
Zhang R; Zhang TT; Zhai GQ; Guo XY; Qin Y; Gan TQ; Zhang Y; Chen G; Mo WJ; Feng ZB
World J Surg Oncol; 2018 Jun; 16(1):109. PubMed ID: 29914539
[TBL] [Abstract][Full Text] [Related]
43. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
44. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma.
Jain D; Nambirajan A; Chen G; Geisinger K; Hiroshima K; Layfield L; Minami Y; Moreira AL; Motoi N; Papotti M; Rekhtman N; Russell PA; Prince SS; Schmitt F; Yatabe Y; Eppenberger-Castori S; Bubendorf L;
J Thorac Oncol; 2022 Jun; 17(6):793-805. PubMed ID: 35331963
[TBL] [Abstract][Full Text] [Related]
45. What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients.
Wang W; Liu H; Li G
Front Endocrinol (Lausanne); 2022; 13():947443. PubMed ID: 36105402
[TBL] [Abstract][Full Text] [Related]
46. Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data.
Lathwal A; Kumar R; Arora C; Raghava GPS
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2743-2752. PubMed ID: 32661603
[TBL] [Abstract][Full Text] [Related]
47. Validation and analysis of expression, prognosis and immune infiltration of WNT gene family in non-small cell lung cancer.
Wang J; Yang Q; Tang M; Liu W
Front Oncol; 2022; 12():911316. PubMed ID: 35957916
[TBL] [Abstract][Full Text] [Related]
48. [Expression and clinical significance of p53 protein and p21(WAF1) in non-small-cell lung carcinoma].
Zhang H; Lü F; Yue W; Yan H; Deng L; Wang S
Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):328-30. PubMed ID: 11866928
[TBL] [Abstract][Full Text] [Related]
49. Abandoning the Notion of Non-Small Cell Lung Cancer.
Relli V; Trerotola M; Guerra E; Alberti S
Trends Mol Med; 2019 Jul; 25(7):585-594. PubMed ID: 31155338
[TBL] [Abstract][Full Text] [Related]
50. A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study.
Lu C; Bera K; Wang X; Prasanna P; Xu J; Janowczyk A; Beig N; Yang M; Fu P; Lewis J; Choi H; Schmid RA; Berezowska S; Schalper K; Rimm D; Velcheti V; Madabhushi A
Lancet Digit Health; 2020 Nov; 2(11):e594-e606. PubMed ID: 33163952
[TBL] [Abstract][Full Text] [Related]
51. Expression of
Zhang X; Nie X; Long J; Yu J; Zhang P; Liu Y; Wu X; Bai Y; Mao J; Liu X; Yuan Y; Zhao H; Li L
Ann Transl Med; 2020 Jul; 8(13):819. PubMed ID: 32793664
[TBL] [Abstract][Full Text] [Related]
52. Precise pathological classification of non-small cell lung adenocarcinoma and squamous carcinoma based on an integrated platform of targeted metabolome and lipidome.
Cao P; Wu S; Guo W; Zhang Q; Gong W; Li Q; Zhang R; Dong X; Xu S; Liu Y; Shi S; Huang Y; Zhang Y
Metabolomics; 2021 Nov; 17(11):98. PubMed ID: 34729658
[TBL] [Abstract][Full Text] [Related]
53. Shared network pattern of lung squamous carcinoma and adenocarcinoma illuminates therapeutic targets for non-small cell lung cancer.
Li P; Kuang X; Zhang T; Ma L
Front Surg; 2022; 9():958479. PubMed ID: 36263088
[TBL] [Abstract][Full Text] [Related]
54. Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: correlation with clinicopathological features and patients' prognosis.
Wei Z; Wang Y; Li Z; Yuan C; Zhang W; Wang D; Ye J; Jiang H; Wu Y; Cheng J
J Oral Pathol Med; 2013 Nov; 42(10):747-54. PubMed ID: 23551691
[TBL] [Abstract][Full Text] [Related]
55. High
Xie L; Dang Y; Guo J; Sun X; Xie T; Zhang L; Yan Z; Amin H; Guo X
Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634629
[TBL] [Abstract][Full Text] [Related]
56. Transcription Factors Contribute to Differential Expression in Cellular Pathways in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Liu S; Wang X; Qin W; Genchev GZ; Lu H
Interdiscip Sci; 2018 Dec; 10(4):836-847. PubMed ID: 30039492
[TBL] [Abstract][Full Text] [Related]
57. Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.
Zhong K; Yang F; Han Q; Chen J; Wang J
Oncol Lett; 2018 Sep; 16(3):2873-2880. PubMed ID: 30127874
[TBL] [Abstract][Full Text] [Related]
58. Potential applications of prognostic and immunological marker transmembrane serine proteinase 2 in prediction, prevention and personalized treatment of lung cancer.
Mu B; Zhang R; Pu Y; Yao J; Hu X; Zhao C
Eur J Cancer Prev; 2023 Jan; 32(1):65-68. PubMed ID: 35170548
[TBL] [Abstract][Full Text] [Related]
59. Multiple mutations of lung squamous cell carcinoma shared common mechanisms.
Li Q; Hou J; Hu Z; Gu B; Shi Y
Oncotarget; 2016 Nov; 7(48):79629-79636. PubMed ID: 27835590
[TBL] [Abstract][Full Text] [Related]
60. Interferon regulatory factor 4 (IRF4) is overexpressed in human non‑small cell lung cancer (NSCLC) and activates the Notch signaling pathway.
Qian Y; Du Z; Xing Y; Zhou T; Chen T; Shi M
Mol Med Rep; 2017 Nov; 16(5):6034-6040. PubMed ID: 28849037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
